Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Journal of Palliative Medicine|September 21, 2010
Preferences of patients with advanced lung cancer regarding the involvement of family and others in medical decision-makingKoen Pardon, Reginald Deschepper, Robert Vander Stichele, et al.American Journal of Respiratory and Critical Care Medicine|January 16, 2010
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, et al.Clinical Lung Cancer|August 1, 2017
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLCNele Van Der Steen, Yves Mentens, Marc Ramael, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2011
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort studyKevin Hollevoet, Joris Van Cleemput, Joël Thimpont, et al.Chest|July 9, 2011
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factorKevin Hollevoet, Kristiaan Nackaerts, Olivier Thas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii studyRonald B Natale, David Bodkin, Ramaswamy Govindan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 16, 2011
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, et al.Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.Plos One|July 15, 2024
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC studyJolien Van den Bossche, Maxime De Laere, Koen Deschepper, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinomaMalcolm V Brock, Mingzhou Gou, Yoshimitsu Akiyama, et al.Pageof 3